Combinatorial Antiviral Therapy (CAT): A pharmaceutical mixture encompassing Gefitinib and Celecoxib  inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytical ,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, & Interferon-stimulated gene 15, 19/December/2017,  11.40 pm

Cardiac rejuvenation therapy: A therapeutic mix encompassing Pyridoxamine (PM) and Sulforaphane (SFN) suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy via up regulation of its target gene, 19/December/2017, 10.54 pm
December 19, 2017
Natural product-derived therapy for anxiety and depression: Rosmarinic acid, isolated from Rosemary Officinalis and Perilla frutescens, decreases PHF8 levels, increases the expression of serotonin receptors Htr1a and Htr2a, and promotes resistance to stress-induced -anxiety and -depression via down regulation of its target gene, 21/December/2017, 6.45am
December 21, 2017
Show all

Introduction: What they say: 

A study from the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard Medical School, Charlestown, MA 02129, USA shows that “The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus.” This study was published, in the 24 December 2009 issue of the journal “Cell” (the number 1 research journal in General Biology with an impact factor of 33),  by the 2015 Laskar award winner Prof. Stephen Elledge, Brass and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Combinatorial Antiviral Therapy (CAT): A pharmaceutical mixture encompassing Gefitinib and Celecoxib  inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytical ,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, & Interferon-stimulated gene 15


What is known?

Prof. Stephen Elledge research team has showed that interferon-inducible transmembrane proteins IFITM1, 2, and 3 inhibit  influenza A H1N1 virus, West Nile virus, and dengue virus replication, suggesting that increasing the expression of IFITM3 may confer resistance against these viruses. Other studies suggest that IFITM3 may also protect against Ebola virus, hepatitis C virus, yellow fever virus and SARS coronavirus etc.


From research findings to therapeutic opportunity: 

This study suggests, for the first time, that a pharmaceutical mixture encompassing  Gefitinib and Celecoxib, by decreasing the expression of its target genes, it may increase the expression of interferon-inducible transmembrane protein IFITM3, Interferon-stimulated gene-15, Mx2 and antimicrobial peptides. Thereby, it may: (1) inhibit the replication of  Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses; (2) confer resistance against  infection caused by Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytical,  Sindbis, and SFV viruses; and (3) promote innate immunity (Figure 1) Thus, pharmacological formulations encompassing “Gefitinib and Celecoxib or their analogues” may be used to prevent/treat infections caused by Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytical,  Sindbis, and SFV viruses (Figure 2).

Figure 1. Mechanistic insight into how a pharmaceutical mixture encompassing Gefitinib and Celecoxib  inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial , Sindbis, and SFV viruses production through induction of its target genes, such as Antiviral Proteins IFITM3, Interferon-stimulated gene 15, & Mx2

 

Figure 2. The chemical structure of Gefitinib and Celecoxib. A pharmaceutical mixture encompassing f Gefitinib and Celecoxib may function as a broad-spectrum antiviral agent against a number of infections caused by viruses.

 

 


Details of the research findings: 

Idea formulated by Dr L Boominathan PhD

Undisclosed information: How a pharmaceutical mixture encompassing Gefitinib and Celecoxib increases the expression of Antiviral Protein IFITM3, , Interferon-stimulated gene 15, & Mx2

Amount: $1, 500

# Research cooperation

For more details on payment, you may reach us at admin@genomediscovery.org


CitationBoominathan L, Combinatorial Antiviral Therapy (CAT): A pharmaceutical mixture encompassing Gefitinib and Celecoxib  inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytical ,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, & Interferon-stimulated gene 15, 19/December/2017,  11.40 pm


Courtesy:
 When you cite drop us a line at info@genomediscovery.org,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Comments are closed.